A novel therapeutic strategy for β-thalassemia (original) (raw)

Efficient gene correction of an aberrant splice site in β‐thalassaemia iPSCs by CRISPR/Cas9 and single‐strand oligodeoxynucleotides

shouheng lin

Journal of Cellular and Molecular Medicine

View PDFchevron_right

Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia

Kevin Luk

Blood, 2019

View PDFchevron_right

Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac

Marcus O Muench

Genome Research, 2014

View PDFchevron_right

Correction of Hemoglobin E/Beta-Thalassemia Patient-Derived iPSCs Using CRISPR/Cas9

Methichit Wattanapanitch

Methods in molecular biology, 2021

View PDFchevron_right

Identification of on-target mutagenesis during correction of a beta-thalassemia splice mutation in iPS cells with optimised CRISPR/Cas9-double nickase reveals potential safety concerns

Ernst Wolvetang

APL Bioengineering

View PDFchevron_right

Generation of an in vitro model of β‐thalassemia using the CRISPR/Cas9 genome editing system

Saeid Kaviani

Journal of Cellular Biochemistry, 2019

View PDFchevron_right

Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia

Sachith Mettananda

Nature communications, 2017

View PDFchevron_right

One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system

Nuttha Klincumhom

Stem Cell Research & Therapy

View PDFchevron_right

Universal Gene Correction Approaches for β-hemoglobinopathies Using CRISPR-Cas9 and Adeno-Associated Virus Serotype 6 Donor Templates

Praveen Baskaran

The CRISPR Journal, 2021

View PDFchevron_right

Gene Therapy for B-thalassemia; New Challenges

International Journal of Science and Healthcare Research (IJSHR)

https://ijshr.com/IJSHR\_Vol.5\_Issue.3\_July2020/IJSHR\_Abstract.0025.html, 2020

View PDFchevron_right

A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease

armaan qasba

STEM CELLS Translational Medicine

View PDFchevron_right

Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β039-Globin Gene Editing and Induction of Fetal Hemoglobin

Lucia Cosenza

Genes

View PDFchevron_right

Genetic correction of haemoglobin E in an immortalised haemoglobin E/beta-thalassaemia cell line using the CRISPR/Cas9 system

Methichit Wattanapanitch

Scientific Reports

View PDFchevron_right

CRISPR, ZFNS, and TALENS for Hemoglobinopathies an Analysis

IJRASET Publication

IJRASET, 2021

View PDFchevron_right

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Tony W Ho

New England Journal of Medicine, 2021

View PDFchevron_right

Highly efficient therapeutic gene editing of human hematopoietic stem cells

Kevin Luk

Nature Medicine, 2019

View PDFchevron_right

The Scope for Thalassemia Gene Therapy by Disruption of Aberrant Regulatory Elements

Michael Antoniou

Journal of Clinical Medicine

View PDFchevron_right

Gene correction of HBB mutations in CD34+ hematopoietic stem cells using Cas9 mRNA and ssODN donors

Praveen Baskaran

Molecular and Cellular Pediatrics, 2018

View PDFchevron_right

Advances in genome editing: the technology of choice for precise and efficient β-thalassemia treatment

Javed Akram

Gene Therapy, 2020

View PDFchevron_right

In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia

Evangelia Yannaki

Journal of Clinical Investigation

View PDFchevron_right

Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements

Zsuzsanna Izsvák

JCI Insight

View PDFchevron_right

Repair of a Splicing Defect in Erythroid Cells from Patients with β-Thalassemia/HbE Disorder

Ryszard Kole

Molecular Therapy, 2002

View PDFchevron_right

Engineered U7 snRNA mediates sustained splicing correction in erythroid cells from β-thalassemia/HbE patients

Suthat Fucharoen

Biochemical and Biophysical Research Communications, 2018

View PDFchevron_right

Recent trends in the gene therapy of β-thalassemia

Nicoletta Bianchi

Journal of Blood Medicine, 2015

View PDFchevron_right

CRISPR to fix bad blood: a new tool in basic and clinical hematology

Rafael Vazquez-Manrique

Haematologica

View PDFchevron_right

Towards More Successful Gene Therapy Clinical Trials for β-Thalassemia

N. Anagnou

Current Molecular Medicine, 2013

View PDFchevron_right

Correction of the Sickle Cell Mutation Through Base and Prime Editing in Hematopoietic Stem Cells

Kelly Ji

View PDFchevron_right

A Review: CRISPR/Cas9-Mediated Genome Editing in Hematopoietic Stem and Progenitor Cells (HSPCs) and Their Applications on Hematological Disorders

LAKSHMI KUMARI

2020

View PDFchevron_right

Hemoglobinopathy Correction with CRISPR or Not; Gene Therapy is the Solution

Bader Al Alwan

Journal of Nature and Science of Medicine, 2020

View PDFchevron_right

Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements

Cecile Masson

Molecular Therapy

View PDFchevron_right

Correction of sickle-cell anemia using CRISPR-Cas9 system in hematopoietic stem cells

Beatriz Draiblate

2020

View PDFchevron_right

High efficiency gene correction in hematopoietic cells by donor-template-free CRISPR/Cas9 genome editing

Stefan Stein

Experimental Hematology, 2017

View PDFchevron_right

Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates

Megan Hoban

Molecular Therapy, 2019

View PDFchevron_right

CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells

Carmen F Bjurström

Molecular Therapy, 2016

View PDFchevron_right